Healthcare Industry News: desmopressin
News Release - September 10, 2008
Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical AffairsPARSIPPANY, N.J., Sept. 10 (HSMN NewsFeed) -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the appointment of Paul Korner, M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be responsible for Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas as well as Product Safety.
"As a result of our continued and projected growth, we have expanded and realigned our management staff to best meet our business needs," said Wayne Anderson, President and CEO. "Dr. Korner is exceptionally well qualified to fill this new role, as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."
Dr. Korner joins Ferring with a broad range of experience in medical affairs, clinical development, management and business development. Prior to joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.
Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA® (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE® (urofollitropin for injection, purified); MENOPUR® (menotropins for injection, USP); REPRONEX® (menotropins for injection, USP); Novarel® (chorionic gonadotropin for injection, USP) and ENDOMETRIN® (progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.
Other products include: ACTHREL® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; desmopressin ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED® DS for the relief of discomfort of the lower urinary tract.
The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit www.FerringUSA.com.
Source: Ferring Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.